Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AACTNASDAQ:CNCKNYSE:FSNBNYSE:IBER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAACTAres Acquisition Corporation II$11.30-0.1%$11.31$10.67▼$11.62$699.64M-0.01407,699 shs27,869 shsCNCKCoincheck Group$6.27+4.5%$6.15$4.22▼$14.42$778.20M0.1163,817 shs46,716 shsFSNBFusion Acquisition Corp. II$10.49$10.49$9.52▼$10.75N/AN/AN/AN/AIBERIbere Pharmaceuticals$10.18$10.17$9.74▼$10.75$175.61MN/A110,000 shs44,499 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAACTAres Acquisition Corporation II-0.04%+0.13%-2.04%+1.48%+5.90%CNCKCoincheck Group+7.91%+20.72%+21.70%+22.45%+599,999,900.00%FSNBFusion Acquisition Corp. II0.00%0.00%0.00%0.00%0.00%IBERIbere Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAACTAres Acquisition Corporation IIN/AN/AN/AN/AN/AN/AN/AN/ACNCKCoincheck Group1.616 of 5 stars3.50.00.00.01.11.70.0FSNBFusion Acquisition Corp. IIN/AN/AN/AN/AN/AN/AN/AN/AIBERIbere PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAACTAres Acquisition Corporation II 0.00N/AN/AN/ACNCKCoincheck Group 3.00Buy$10.0059.49% UpsideFSNBFusion Acquisition Corp. II 0.00N/AN/AN/AIBERIbere Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAACTAres Acquisition Corporation IIN/AN/A$0.42 per share27.20($0.35) per shareN/ACNCKCoincheck Group$2.56B0.32N/AN/A$0.55 per share11.40FSNBFusion Acquisition Corp. IIN/AN/AN/AN/AN/AN/AIBERIbere PharmaceuticalsN/AN/A$0.09 per share112.42($0.63) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAACTAres Acquisition Corporation II$25.99MN/A0.00∞N/AN/A-101.04%4.12%8/4/2025 (Estimated)CNCKCoincheck Group-$95.70MN/A0.00∞N/AN/A-359.24%-4.64%N/AFSNBFusion Acquisition Corp. II$16.57MN/A0.00∞N/AN/AN/AN/AN/AIBERIbere Pharmaceuticals$1.56MN/A0.00∞N/AN/A-83.01%4.47%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAACTAres Acquisition Corporation IIN/AN/AN/AN/AN/ACNCKCoincheck GroupN/AN/AN/AN/AN/AFSNBFusion Acquisition Corp. IIN/AN/AN/AN/AN/AIBERIbere PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAACTAres Acquisition Corporation IIN/A0.240.24CNCKCoincheck GroupN/A1.071.01FSNBFusion Acquisition Corp. IIN/AN/AN/AIBERIbere PharmaceuticalsN/A0.240.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAACTAres Acquisition Corporation II72.95%CNCKCoincheck Group33.22%FSNBFusion Acquisition Corp. IIN/AIBERIbere Pharmaceuticals69.66%Insider OwnershipCompanyInsider OwnershipAACTAres Acquisition Corporation IIN/ACNCKCoincheck Group65.10%FSNBFusion Acquisition Corp. II73.64%IBERIbere Pharmaceuticals20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAACTAres Acquisition Corporation IIN/A61.86 millionN/ANot OptionableCNCKCoincheck GroupN/A129.70 million45.27 millionN/AFSNBFusion Acquisition Corp. II214.69 million3.87 millionNot OptionableIBERIbere Pharmaceuticals317.25 million13.80 millionNot OptionableIBER, AACT, FSNB, and CNCK HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeAT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?By Jeffrey Neal Johnson | June 5, 2025View AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?IBER, AACT, FSNB, and CNCK Company DescriptionsAres Acquisition Corporation II NYSE:AACT$11.30 -0.01 (-0.09%) As of 03:30 PM EasternAres Acquisition Corp. II is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on March 15, 2021 and is headquartered in New York, NY.Coincheck Group NASDAQ:CNCK$6.27 +0.27 (+4.50%) As of 01:00 PM EasternCoincheck Group NV. is a Dutch public limited liability company and a holding company of Coincheck, Inc. which operates one of the largest multi-cryptocurrency marketplaces and crypto asset exchanges in Japan and is regulated by the Financial Services Agency of Japan. The company was founded on February 18, 2022 and is headquartered in Amsterdam, Netherland.Fusion Acquisition Corp. II NYSE:FSNB$10.49 0.00 (0.00%) As of 07/1/2025Fusion Acquisition Corp. II does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to acquire businesses in the wealth, financial advice, investment, and asset management sectors, as well as FinTech sector. Fusion Acquisition Corp. II was incorporated in 2021 and is based in New York, New York.Ibere Pharmaceuticals NYSE:IBERIbere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
